ConSynance wins FDA designation for Prader-Willi syndrome therapy

A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.

Jul 26, 2024 - 04:00

ConSynance wins FDA designation for Prader-Willi syndrome therapy

A Phase II study for ConSynance’s triple monoamine reuptake inhibitor CSTI-500 is slated to begin in 2025.

Read the original article

Tags:

Previous Article

Sandoz launches ustekinumab biosimilar in Europe

FDA agrees wider use of BioMarin’s BRINEURA for CLN2

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Sanofi inaugurates vaccine plant in Neuville-sur-Saône, France

Sanofi inaugurates vaccine plant in Neuville-sur-Saône,...

Sep 12, 2024

HCA Healthcare gets grant for wrist brace with advantag...

Apr 5, 2024

Fresh produce access boosts health outcomes among diabetes patients and those on Medicaid in recent studies

Fresh produce access boosts health outcomes among diabe...

Nov 15, 2023